Upcoming Presentations

ISHLT 28th Annual Meeting & Scientific Sessions. April 10, 2008. Boston, MA Daniel Goldstein MD, Yoshifumi Naka MD, Timothy Icenogle MD, Mark Slaughter MD, et al. "The Epidemiology of Bleeding and Clotting in Pulsatile and Continuous Flow LVAD Patients."(Accepted for Oral Presentation)
Platelet Activation in Patients Supported by Continuous Flow Left Ventricular Assist Devices. ISHLT 28th Annual Meeting & Scientific Sessions. Mark S Slaughter, MD, Michael A Sobieski, CCP, Joel D Graham, et al. "Cardiac Surgery Research and Mechanical Assist Device Program . . . " (Accepted for Oral Presentation)
ISHLT 28th Annual Meeting & Scientific Sessions. Nutter AL, Slaughter MS, Silver MA. "A Decline in the VE/VCO2 Slope from Anaerobic Threshold to Peak Exercise Predicts Short Term Need for LVAD or Heart Transplant."(Accepted for Oral Presentation)
more

Tel. (630) 789-2296

Myocardial Assist Systems and Technology, LLC
Harris Avenue
Clarendon Hills, IL 60514

Clinical Trials

LVAD Clinical Trials and MASTLocated in the third-largest population center in the U.S.—and working with Advocate Christ Medical Center, one of the premier cardiovascular transplant and surgery centers in the nation—MAST offers an excellent opportunity for medical device corporations seeking clinical trial participants.

Device manufacturers are finding an increasing number of regulatory groups and guidelines involved with every medical device clinical trial. MAST offers the clinical trial expertise that these companies need to evolve from pre-trial through Phase IV Trials and on to market, including process management and properly controlled and managed documentation. Dr. Slaughter has been an investigator or Principal Investigator—often in collaboration with MAST associate Michael Sobieski—for more than 35 clinical trials over the past 10 years, including the more recent:

  • A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nl Staphylococcus aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery. (Merck) 2008-Present.
  • A Prospective, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-Center Study to evaluate the efficacy of activated recombinant Factor VII for early control of hemorrhage in high-risk cardiac surgery. (NovoNordisk) 2008-Present.
  • Rheox Baroreflex Hypertension Therapy System Pivotal Trial. (CVRX) 2007–Present.
  • Rheox Baroreflex Hypertension Therapy System Feasibility Trial. (CVRX) 2006-2007.
    • The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation of Left Ventricular Assist Devices. (SCCOR) 2006-Present.
    • The Epidemiology of Ventricular Assist Devices – Related Infections. (SCCOR) 2006-Present.
    • Momentum Trial: Multicenter Trial of the Oriqis CRS for the Enhanced Treatment of CHF Unresponsive to Medical Therapy. 2006-Present.
    • A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Human Recombinant Soluable Complement Receptor Type 1 (TP10) in Adult Women Undergoing Cardiopulmonary Bypass Surgery. 2005-Present.
    • HeartMate II LVAS Pivotal Study. 2005-Present.
    • Pathophysiciologic Benefits of Continuous and Pulsatile Ventricular Assist Trial. 2004-Present.
    • A Phase I Study of the Safety and Pharmacokinetics of Recombinant Factor XIII- Administration in Patients Undergoing First-time Cardiopulmonary Bypass for Myocardial Revascularization. (ZymoGenetics) 2003.
    • Mitral Valve Replacement using the daVinci Surgical System. 2003-Present.
    • HeartMate LVAS Cardiogenic Shock Complicating An Acute Myocardial Infarction. 2003-Present.
    • Thoratec Destination Therapy Registry. 2003-Present.
    • ISHLT Mechanical Circulatory Support Device Database. 2002-Present.
    Clinical Trials LVAD Research and Design Cardiac Device Program Consulting